Chronic Progressive External Ophthalmoplegia (CPEO/PEO) Panel
Summary and Pricing
Test Method
Exome Sequencing with CNV DetectionTest Code | Test Copy Genes | Panel CPT Code | Gene CPT Codes Copy CPT Code | Base Price | |
---|---|---|---|---|---|
10507 | Genes x (13) | 81479 | 81404(x2), 81405(x5), 81406(x3), 81407(x1), 81479(x15) | $990 | Order Options and Pricing |
Pricing Comments
We are happy to accommodate requests for testing single genes in this panel or a subset of these genes. The price will remain the list price. If desired, free reflex testing to remaining genes on panel is available. Alternatively, a single gene or subset of genes can also be ordered via our Custom Panel tool.
An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.
Click here for costs to reflex to whole PGxome (if original test is on PGxome Sequencing platform).
Click here for costs to reflex to whole PGnome (if original test is on PGnome Sequencing platform).
Turnaround Time
3 weeks on average for standard orders or 2 weeks on average for STAT orders.
Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.
Targeted Testing
For ordering sequencing of targeted known variants, go to our Targeted Variants page.
Clinical Features and Genetics
Clinical Features
The accumulation of multiple mtDNA deletions can be a sign of the cell’s inability to maintain mitochondrial genome integrity. Multiple mtDNA deletions are typically seen in the skeletal muscle of patients affected by adult-onset chronic progressive external ophthalmoplegia (weakness of the extraocular muscles, referred to as CPEO or PEO), a disorder that is often accompanied by ptosis, oropharyngeal weakness, and proximal limb weakness (DiMauro and Hirano. 2011. PubMed ID: 20301382). Onset typically ranges between 20-40 years of age (Viscomi and Zeviani. 2017. PubMed ID: 28324239). In contrast to many other mitochondrial diseases, isolated CPEO is a relatively mild phenotype.
When patients display additional, often more severe phenotypes beyond those of the isolated form, this may be referred to as chronic progressive external ophthalmoplegia plus (CPEO+/PEO+). Additional symptoms are often multi-systemic and can include ataxia, psychiatric symptoms, sensory axonal neuropathy, hearing loss and/or optic atrophy, among others (Sommerville et al. 2014. PubMed ID: 27858775; Hanisch et al. 2015. PubMed ID: 25143630). At this time, genotype-phenotype correlation for this spectrum of disease is poorly understood.
Muscle biopsies of patients affected with CPEO are distinguished by the presence of ragged red fibers, a characteristic finding under modified Gomori trichrome staining that is explained by the accumulation of abnormal mitochondria within the subsarcolemmal space (DiMauro and Hirano. 2011. PubMed ID: 20301382; Viscomi and Zeviani. 2017. PubMed ID: 28324239). Patients generally present with decreased activities of the respiratory chain complexes, a consequence of reduced mitochondrial genome integrity, and histochemical staining for cytochrome c oxidase (COX, complex IV) is also either decreased or absent (Viscomi and Zeviani. 2017. PubMed ID: 28324239).
Genetics
Chronic progressive external ophthalmoplegia (CPEO) can be caused by defects in one of a number of genes within the nuclear genome: DGUOK, DNA2, MGME1, OPA1, POLG, POLG2, RNASEH1, RRM2B, SLC25A4, SPG7, TK2, TWNK, or TYMP. Inheritance may be primarily autosomal dominant (POLG2, OPA1, DNA2, SLC25A4) or autosomal recessive (DGUOK, MGME1, RNASEH1, TK2, TYMP), while reports of both recessive and dominant inheritance have been documented for a subset of genes (POLG, RRM2B, TWNK, SPG7).
Please note that CPEO may also present in individuals who harbor de novo or maternally-inherited mtDNA deletions, or pathogenic single nucleotide variants in the mitochondrial genome (DiMauro and Hirano. 2011. PubMed ID: 20301382; Chinnery. 2014. PubMed ID: 20301403). Sequencing of the mitochondrial genome is not offered as part of this test, but could be considered in individuals who test negative for plausible causative variants in the nuclear genes associated with this disorder.
Clinical Sensitivity - Sequencing with CNV PGxome
Based on a 2014 literature review by Sommerville et al., POLG and TWNK are likely the most common nuclear-encoded genes known to be responsible for chronic progressive external ophthalmoplegia; at the time of publishing, 258 and 143 patients, respectively, had been reported (Sommerville et al. 2014. PubMed ID: 27858775). TYMP, RRM2B, OPA1, and SLC25A4 were found in 30-50 patients each, while SPG7, MGME1, TK2, POLG2, DGUOK, DNA2, and MPV17 were less common causes of disease (<13 individuals each).
Testing Strategy
This test is performed using Next-Gen sequencing with additional Sanger sequencing as necessary.
This panel provides 100% coverage of all coding exons of the genes plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define coverage as ≥20X NGS reads or Sanger sequencing. PGnome panels typically provide slightly increased coverage over the PGxome equivalent. PGnome sequencing panels have the added benefit of additional analysis and reporting of deep intronic regions (where applicable).
Dependent on the sequencing backbone selected for this testing, discounted reflex testing to any other similar backbone-based test is available (i.e., PGxome panel to whole PGxome; PGnome panel to whole PGnome).
Indications for Test
Individuals who present with suspected autosomal dominant or autosomal recessive adult-onset chronic progressive external ophthalmoplegia are good candidates for this test.
Individuals who present with suspected autosomal dominant or autosomal recessive adult-onset chronic progressive external ophthalmoplegia are good candidates for this test.
Genes
Official Gene Symbol | OMIM ID |
---|---|
DGUOK | 601465 |
DNA2 | 601810 |
MGME1 | 615076 |
OPA1 | 605290 |
POLG | 174763 |
POLG2 | 604983 |
RNASEH1 | 604123 |
RRM2B | 604712 |
SLC25A4 | 103220 |
SPG7 | 602783 |
TK2 | 188250 |
TWNK | 606075 |
TYMP | 131222 |
Inheritance | Abbreviation |
---|---|
Autosomal Dominant | AD |
Autosomal Recessive | AR |
X-Linked | XL |
Mitochondrial | MT |
Diseases
Related Test
Name |
---|
PGxome® |
Citations
Ordering/Specimens
Ordering Options
We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.
myPrevent - Online Ordering
- The test can be added to your online orders in the Summary and Pricing section.
- Once the test has been added log in to myPrevent to fill out an online requisition form.
- PGnome sequencing panels can be ordered via the myPrevent portal only at this time.
Requisition Form
- A completed requisition form must accompany all specimens.
- Billing information along with specimen and shipping instructions are within the requisition form.
- All testing must be ordered by a qualified healthcare provider.
For Requisition Forms, visit our Forms page
If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.
Specimen Types
Specimen Requirements and Shipping Details
PGxome (Exome) Sequencing Panel
PGnome (Genome) Sequencing Panel
ORDER OPTIONS
View Ordering Instructions1) Select Test Type
2) Select Additional Test Options
No Additional Test Options are available for this test.